Pediatric oral solutions with propranolol hydrochloride for extemporaneous compounding: the formulation and stability study
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
23578266
PII: 40144
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Chemistry, Pharmaceutical MeSH
- Hydrogen-Ion Concentration MeSH
- Humans MeSH
- Drug Compounding MeSH
- Propranolol * MeSH
- Solutions MeSH
- Drug Stability * MeSH
- Temperature MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Propranolol * MeSH
- Solutions MeSH
UNLABELLED: The aim of this study is to formulate an extemporaneous pediatric oral solution of propranolol hydrochloride (PRO) 2 mg/ml for the therapy of infantile haemangioma or hypertension in a target age group of 1 month to school children and to evaluate its stability. A citric acid solution and/or a citrate-phosphate buffer solution, respectively, were used as the vehicles to achieve pH value of about 3, optimal for the stability of PRO. In order to mask the bitter taste of PRO, simple syrup was used as the sweetener. All solutions were stored in tightly closed brown glass bottles at 5 ± 3 °C and/or 25 ± 3 °C, respectively. The validated HPLC method was used to evaluate the concentration of PRO and a preservative, sodium benzoate, at time intervals of 0-180 days. All preparations were stable at both storage temperatures with pH values in the range of 2.8-3.2. According to pharmacopoeial requirements, the efficacy of sodium benzoate 0.05 % w/v was proved (Ph.Eur., 5.1.3). The preparation formulated with the citrate-phosphate buffer, in our experience, had better palatability than that formulated with the citric acid solution. KEYWORDS: propranolol hydrochloride pediatric preparation extemporaneous preparation solution stability testing HPLC.